inhibitor Lynparza (olaparib) as a first-line treatment of women with breast cancer gene (BRCA) non-mutated advanced epithelial ovarian cancer. Patients on the trial will have just undergone PDS or be ...

In a rough day for PARP inhibitors in ovarian cancer, GSK’s Zejula didn’t deliver a life extension benefit in the final ...

Adding a PD-1 inhibitor to PARP inhibitor maintenance therapy failed to slow progression or improve survival in newly ...

Elahere was found to improve survival in patients with FR-alpha–positive, platinum-resistant, high-grade serous epithelial ...

Patients with platinum-sensitive relapsed ovarian cancer given maintenance olaparib/cediranib had similar progression-free ...

Mirvetuximab soravtansine showed high evidence of efficacy in heavily pretreated FRα-positive, platinum-sensitive ovarian ...

Mirvetuximab soravtansine was the first ADC to show efficacy as a therapy for platinum-resistant ovarian cancer. Despite high ...

The newly launched “What Science Can Do” campaign, a longstanding tagline for AstraZeneca, centers around the stories of two patients who have benefitted from the company’s therapeutics. Each of their ...

Durable Clinical Benefit Observed Beyond a Year on Treatment in Heavily Pre-Treated PatientsBoston (September 16, 2024) — Allarity ...

Scientists have pinpointed thousands of genetic changes in a gene that may increase a person's risk of developing breast and ...

New research identifies specific genetic changes that can increase a person's risk of breast and ovarian cancers, to help guide clinical decision-making.

Meet the Management at ESMO 2024 Conference September 16, 2024 2:00 PM ETCompany ParticipantsPascal Soriot - Chief ...